Medizinische Universität Graz - Research portal

Navigation/Search

• Researchers.
• Institutions.
• Projects.
• Publications.
• Partners.
• Sponsors.
• Equipment.
• Knowhow.
• Fields of Research.

Publications

Search Items: LUNG NEOPLASMS - DRUG THERAPY , . hits: 53

2022

Dankner, M; Wang, Y; Fazelzad, R; Johnson, B; Nebhan, CA; Dagogo-Jack, I; Myall, NJ; Richtig, G; Bracht, JWP; Gerlinger, M; Shinozaki, E; Yoshino, T; Kotani, D; Fangusaro, JR; Gautschi, O; Mazieres, J; Sosman, JA; Kopetz, S; Subbiah, V; Davies, MA; Groover, AL; Sullivan, RJ; Flaherty, KT; Johnson, DB; Benedetti, A; Cescon, DW; Spreafico, A; Zogopoulos, G; Rose, AAN Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.
JCO Precis Oncol. 2022; 6:e2200107 Doi: 10.1200/PO.22.00107
PubMed FullText FullText_MUG

 

2021

Geiger-Gritsch, S; Olschewski, H; Kocher, F; Wurm, R; Absenger, G; Flicker, M; Hermann, A; Heininger, P; Fiegl, M; Zechmeister, M; Endel, F; Wild, C; Pall, G Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer : A retrospective Austrian multicenter study.
Wien Klin Wochenschr. 2021; 133(21-22):1122-1130 Doi: 10.1007/s00508-021-01940-w
Web of Science PubMed FullText FullText_MUG

 

2019

Kargl, J; Zhu, X; Zhang, H; Yang, GHY; Friesen, TJ; Shipley, M; Maeda, DY; Zebala, JA; McKay-Fleisch, J; Meredith, G; Mashadi-Hossein, A; Baik, C; Pierce, RH; Redman, MW; Thompson, JC; Albelda, SM; Bolouri, H; Houghton, AM Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC.
JCI Insight. 2019; 4(24): Doi: 10.1172/jci.insight.130850 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2018

Buder, A; Hochmair, MJ; Schwab, S; Bundalo, T; Schenk, P; Errhalt, P; Mikes, RE; Absenger, G; Patocka, K; Baumgartner, B; Setinek, U; Burghuber, OC; Prosch, H; Pirker, R; Filipits, M Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
J Thorac Oncol. 2018; 13(6):821-830 Doi: 10.1016/j.jtho.2018.02.014 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gandhi, L; Rodríguez-Abreu, D; Gadgeel, S; Esteban, E; Felip, E; De Angelis, F; Domine, M; Clingan, P; Hochmair, MJ; Powell, SF; Cheng, SY; Bischoff, HG; Peled, N; Grossi, F; Jennens, RR; Reck, M; Hui, R; Garon, EB; Boyer, M; Rubio-Viqueira, B; Novello, S; Kurata, T; Gray, JE; Vida, J; Wei, Z; Yang, J; Raftopoulos, H; Pietanza, MC; Garassino, MC; KEYNOTE-189 Investigators Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med. 2018; 378(22): 2078-2092. Doi: 10.1056/NEJMoa1801005
Web of Science PubMed FullText FullText_MUG

 

Leitinger, M; Varosanec, MV; Pikija, S; Wass, RE; Bandke, D; Weis, S; Studnicka, M; Grinzinger, S; McCoy, MR; Hauer, L; Sellner, J Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature.
Front Immunol. 2018; 9(1): 108-108. Doi: 10.3389/fimmu.2018.00108 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Mairinger, FD; Vollbrecht, C; Flom, E; Christoph, DC; Schmid, KW; Kollmeier, J; Popper, HH; Mairinger, T; Walter, RFH Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Oncotarget. 2017; 8(23):37502-37510 Doi: 10.18632/oncotarget.16398 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Rao, S; Sigl, V; Wimmer, RA; Novatchkova, M; Jais, A; Wagner, G; Handschuh, S; Uribesalgo, I; Hagelkruys, A; Kozieradzki, I; Tortola, L; Nitsch, R; Cronin, SJ; Orthofer, M; Branstetter, D; Canon, J; Rossi, J; D'Arcangelo, M; Botling, J; Micke, P; Fleur, L; Edlund, K; Bergqvist, M; Ekman, S; Lendl, T; Popper, H; Takayanagi, H; Kenner, L; Hirsch, FR; Dougall, W; Penninger, JM RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer.
Genes Dev. 2017; 31(20):2099-2112 Doi: 10.1101/gad.304162.117 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Su, Y; Hu, Y; Wang, Y; Xu, X; Yuan, Y; Li, Y; Wang, Z; Chen, K; Zhang, F; Ding, X; Li, M; Zhou, J; Liu, Y; Wang, W A precision-guided MWNT mediated reawakening the sunk synergy in RAS for anti-angiogenesis lung cancer therapy.
Biomaterials. 2017; 139(28):75-90 Doi: 10.1016/j.biomaterials.2017.05.046
Web of Science PubMed FullText FullText_MUG

 

2015

Ghanim, B; Klikovits, T; Hoda, MA; Lang, G; Szirtes, I; Setinek, U; Rozsas, A; Renyi-Vamos, F; Laszlo, V; Grusch, M; Filipits, M; Scheed, A; Jakopovic, M; Samarzija, M; Brcic, L; Stancic-Rokotov, D; Kern, I; Rozman, A; Dekan, G; Klepetko, W; Berger, W; Glasz, T; Dome, B; Hegedus, B Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
Br J Cancer. 2015; 112(5): 783-792. Doi: 10.1038/bjc.2015.9 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Grabner, B; Schramek, D; Mueller, KM; Moll, HP; Svinka, J; Hoffmann, T; Bauer, E; Blaas, L; Hruschka, N; Zboray, K; Stiedl, P; Nivarthi, H; Bogner, E; Gruber, W; Mohr, T; Zwick, RH; Kenner, L; Poli, V; Aberger, F; Stoiber, D; Egger, G; Esterbauer, H; Zuber, J; Moriggl, R; Eferl, R; Győrffy, B; Penninger, JM; Popper, H; Casanova, E Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.
Nat Commun. 2015; 6(4):6285-6285 Doi: 10.1038/ncomms7285 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hecimovic, A; Jakopovic, M; Pavlisa, G; Jankovic, M; Vukic-Dugac, A; Redzepi, G; Brcic, L; Samarzija, M; Gupta, N SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.
Lymphology. 2015; 48(2):97-102
Web of Science PubMed

 

Hilbe, W; Pall, G; Kocher, F; Pircher, A; Zabernigg, A; Schmid, T; Schumacher, M; Jamnig, H; Fiegl, M; Gächter, A; Freund, M; Kendler, D; Manzl, C; Zelger, B; Popper, H; Wöll, E Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study).
PLoS One. 2015; 10(5):e0125364-e0125364 Doi: 10.1371/journal.pone.0125364 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Obenauf, AC; Zou, Y; Ji, AL; Vanharanta, S; Shu, W; Shi, H; Kong, X; Bosenberg, MC; Wiesner, T; Rosen, N; Lo, RS; Massagué, J Therapy-induced tumour secretomes promote resistance and tumour progression.
Nature. 2015; 520(7547): 368-372. Doi: 10.1038/nature14336 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Tsao, MS; Marguet, S; Le Teuff, G; Lantuejoul, S; Shepherd, FA; Seymour, L; Kratzke, R; Graziano, SL; Popper, HH; Rosell, R; Douillard, JY; Le-Chevalier, T; Pignon, JP; Soria, JC; Brambilla, EM Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.
J Clin Oncol. 2015; 33(30):3439-3446 Doi: 10.1200/JCO.2014.58.8335 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Ediebah, DE; Coens, C; Zikos, E; Quinten, C; Ringash, J; King, MT; Schmucker von Koch, J; Gotay, C; Greimel, E; Flechtner, H; Weis, J; Reeve, BB; Smit, EF; Taphoorn, MJ; Bottomley, A Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.
Br J Cancer. 2014; 110(10):2427-2433 Doi: 10.1038/bjc.2014.208 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Ghanim, B; Hoda, MA; Klikovits, T; Winter, MP; Alimohammadi, A; Grusch, M; Dome, B; Arns, M; Schenk, P; Jakopovic, M; Samarzija, M; Brcic, L; Filipits, M; Laszlo, V; Klepetko, W; Berger, W; Hegedus, B Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.
Br J Cancer. 2014; 110(4): 984-990. Doi: 10.1038/bjc.2013.815 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Joshi, N; Shirsath, N; Singh, A; Joshi, KS; Banerjee, R Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases.
Sci Rep. 2014; 4:7085-7085 Doi: 10.1038/srep07085 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pircher, A; Manzl, C; Fiegl, M; Popper, H; Pirker, R; Hilbe, W Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Lung Cancer. 2014; 83(3): 408-410. Doi: 10.1016/j.lungcan.2013.12.007 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Schelch, K; Hoda, MA; Klikovits, T; Münzker, J; Ghanim, B; Wagner, C; Garay, T; Laszlo, V; Setinek, U; Dome, B; Filipits, M; Pirker, C; Heffeter, P; Selzer, E; Tovari, J; Torok, S; Kenessey, I; Holzmann, K; Grasl-Kraupp, B; Marian, B; Klepetko, W; Berger, W; Hegedus, B; Grusch, M Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
Am J Respir Crit Care Med. 2014; 190(7):763-772 Doi: 10.1164/rccm.201404-0658OC
Web of Science PubMed FullText FullText_MUG

 

2013

Eisner, F; Schaberl-Moser, R; Gerger, A; Samonigg, H; Pichler, M Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Onkologie. 2013; 36(6):368-370 Doi: 10.1159/000351252 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Olaussen, KA; Adam, J; Vanhecke, E; Vielh, P; Pirker, R; Friboulet, L; Popper, H; Robin, A; Commo, F; Thomale, J; Kayitalire, L; Filipits, M; Le Chevalier, T; André, F; Brambilla, E; Soria, JC PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Lung Cancer. 2013; 80(2):216-222 Doi: 10.1016/j.lungcan.2013.01.014 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Shirsath, N; Rathos, M; Chaudhari, U; Sivaramakrishnan, H; Joshi, K Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Lung Cancer. 2013; 82(2):214-221 Doi: 10.1016/j.lungcan.2013.08.010
Web of Science PubMed FullText FullText_MUG

 

2012

Fröhlich, E; Wahl, R Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types?
Diabetes Obes Metab. 2012; 14(3): 204-213. Doi: 10.1111/j.1463-1326.2011.01491.x
Web of Science PubMed FullText FullText_MUG

 

Henzler, T; Konstandin, S; Schmid-Bindert, G; Apfaltrer, P; Haneder, S; Wenz, F; Schad, L; Manegold, C; Schoenberg, SO; Fink, C Imaging of tumor viability in lung cancer: initial results using 23Na-MRI.
Rofo. 2012; 184(4):340-344 Doi: 10.1055/s-0031-1299277
Web of Science PubMed FullText FullText_MUG

 

2011

Popper, H; Wrba, F; Gruber-Mösenbacher, U; Hulla, W; Pirker, R; Hilbe, W; Studnicka, M; Mohn-Staudner, A; Ploner, F; und die Arbeitsgruppe Pulmopathologie der ÖGP-IAP Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer.
Wien Klin Wochenschr. 2011; 123(9-10):316-321 Doi: 10.1007/s00508-011-1573-8
Web of Science PubMed FullText FullText_MUG

 

2010

Hanzer, M; Nebl, A; Spendel, S; Pilhatsch, A; Urban, C; Benesch, M Necrosis of a skin autograft after short-term treatment with sunitinib in a 14-year-old girl with metastatic alveolar soft part sarcoma of the thigh.
Klin Padiatr. 2010; 222(3): 184-186. Doi: 10.1055/s-0030-1249093
Web of Science PubMed FullText FullText_MUG

 

Voortman, J; Goto, A; Mendiboure, J; Sohn, JJ; Schetter, AJ; Saito, M; Dunant, A; Pham, TC; Petrini, I; Lee, A; Khan, MA; Hainaut, P; Pignon, JP; Brambilla, E; Popper, HH; Filipits, M; Harris, CC; Giaccone, G MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non-Small Cell Lung Carcinoma.
Cancer Res. 2010; 70(21): 8288-8298. Doi: 10.1158/0008-5472.CAN-10-1348 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2009

Leithner, K; Stacher, E; Wurm, R; Ploner, F; Quehenberger, F; Wohlkoenig, C; Bálint, Z; Polachova, J; Olschewski, A; Samonigg, H; Popper, HH; Olschewski, H Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
Lung Cancer. 2009; 65(1):98-104 Doi: 10.1016/j.lungcan.2008.10.015
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2008

Hauschild, A; Dummer, R; Ugurel, S; Kaehler, KC; Egberts, F; Fink, W; Both-Skalsky, J; Laetsch, B; Schadendorf, D Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
Cancer. 2008; 113(6):1404-1411 Doi: 10.1002/cncr.23722 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kidd, M; Drozdov, I; Joseph, R; Pfragner, R; Culler, M; Modlin, I Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.
Cancer. 2008; 113(4): 690-700. Doi: 10.1002/cncr.23700 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kidd, M; Schally, AV; Pfragner, R; Malfertheiner, MV; Modlin, IM Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
Cancer. 2008; 112(6): 1404-1414. Doi: 10.1002/cncr.23303 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Leyvraz, S; Pampallona, S; Martinelli, G; Ploner, F; Perey, L; Aversa, S; Peters, S; Brunsvig, P; Montes, A; Lange, A; Yilmaz, U; Rosti, G; Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
J Natl Cancer Inst. 2008; 100(8): 533-541. Doi: 10.1093/jnci/djn088 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2007

Filipits, M; Haddad, V; Schmid, K; Huynh, A; Dunant, A; André, F; Brambilla, E; Stahel, R; Pignon, JP; Soria, JC; Popper, HH; Le Chevalier, T; Pirker, R Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program.
Clin Cancer Res. 2007; 13(13): 3892-3898. Doi: 10.1158/1078-0432.CCR-06-2446 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Filipits, M; Pirker, R; Dunant, A; Lantuejoul, S; Schmid, K; Huynh, A; Haddad, V; André, F; Stahel, R; Pignon, JP; Soria, JC; Popper, HH; Le Chevalier, T; Brambilla, E Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
J Clin Oncol. 2007; 25(19): 2735-2740. Doi: 10.1200/JCO.2006.08.2867 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Ploner, F NSCLC: update on second line therapy following ASCO 2007
Wien Med Wochenschr. 2007; 157(21-22): 540-544. Doi: 10.1007/s10354-007-0481-z
PubMed FullText FullText_MUG

 

Terheyden, P; Hofmann, MA; Weininger, M; Brocker, EB; Becker, JC Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma.
J Cancer Res Clin Oncol. 2007; 133(11):897-901 Doi: 10.1007/s00432-007-0251-8 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2006

Betticher, DC; Hsu Schmitz, SF; Tötsch, M; Hansen, E; Joss, C; von Briel, C; Schmid, RA; Pless, M; Habicht, J; Roth, AD; Spiliopoulos, A; Stahel, R; Weder, W; Stupp, R; Egli, F; Furrer, M; Honegger, H; Wernli, M; Cerny, T; Ris, HB; Swiss Group for Clinical Cancer Research (SAKK) Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
Br J Cancer. 2006; 94(8):1099-1106 Doi: 10.1038/sj.bjc.6603075 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hofmann, G; Bauernhofer, T; Krippl, P; Lang-Loidolt, D; Horn, S; Goessler, W; Schippinger, W; Ploner, F; Stoeger, H; Samonigg, H Plasmapheresis reverses all side-effects of a cisplatin overdose--a case report and treatment recommendation.
BMC Cancer. 2006; 6(2):1-1 Doi: 10.1186/1471-2407-6-1 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Olaussen, KA; Dunant, A; Fouret, P; Brambilla, E; André, F; Haddad, V; Taranchon, E; Filipits, M; Pirker, R; Popper, HH; Stahel, R; Sabatier, L; Pignon, JP; Tursz, T; Le Chevalier, T; Soria, JC; IALT Bio Investigators DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
N ENGL J MED. 2006; 355: 983-991. Doi: 10.1056/NEJMoa060570 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pohl, G; Krajnik, G; Malayeri, R; Müller, RM; Klepetko, W; Eckersberger, F; Schäfer-Prokop, C; Pokrajac, B; Schmeikal, S; Maier, A; Ambrosch, G; Woltsche, M; Minar, W; Pirker, R Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer.
Lung Cancer. 2006; 54(1):63-67 Doi: 10.1016/j.lungcan.2006.05.027
Web of Science PubMed FullText FullText_MUG

 

2004

Glaus, A; Knipping, C; Morant, R; Böhme, C; Lebert, B; Beldermann, F; Glawogger, B; Ortega, PF; Hüsler, A; Deuson, R Chemotherapy-induced nausea and vomiting in routine practice: a European perspective.
Support Care Cancer. 2004; 12(10):708-715 Doi: 10.1007/s00520-004-0662-x
Web of Science PubMed FullText FullText_MUG

 

Helige, C; Hofmann-Wellenhof, R; Fink-Puches, R; Smolle, J Mofarotene-induced inhibition of melanoma cell motility by increasing vinculin-containing focal contacts.
MELANOMA RES. 2004; 14(6): 547-554. Doi: 10.1097%2F00008390-200412000-00018
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Hrzenjak, A; Reicher, H; Wintersperger, A; Steinecker-Frohnwieser, B; Sedlmayr, P; Schmidt, H; Nakamura, T; Malle, E; Sattler, W Inhibition of lung carcinoma cell growth by high density lipoprotein-associated alpha-tocopheryl-succinate.
CELL MOL LIFE SCI. 2004; 61(12): 1520-1531. Doi: 10.1007/s00018-004-4101-4
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Richtig, E; Hofmann-Wellenhof, R; Pehamberger, H; Forstinger, Ch; Wolff, K; Mischer, P; Raml, J; Fritsch, P; Zelger, B; Ratzinger, G; Koller, J; Lang, A; Konrad, K; Kindermann-Glebowski, E; Seeber, A; Steiner, A; Fialla, R; Pachinger, W; Kos, C; Klein, G; Kehrer, H; Kerl, H; Ulmer, H; Smolle, J Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
BRIT J DERMATOL. 2004; 151(1): 91-98. Doi: 10.1111/j.1365-2133.2004.06019.x
Web of Science PubMed FullText FullText_MUG

 

2003

Betticher, DC; Hsu Schmitz, SF; Tötsch, M; Hansen, E; Joss, C; von Briel, C; Schmid, RA; Pless, M; Habicht, J; Roth, AD; Spiliopoulos, A; Stahel, R; Weder, W; Stupp, R; Egli, F; Furrer, M; Honegger, H; Wernli, M; Cerny, T; Ris, HB Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
J Clin Oncol. 2003; 21(9):1752-1759 Doi: 10.1200/JCO.2003.11.040 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2002

Heidemann, E; Stoeger, H; Souchon, R; Hirschmann, WD; Bodenstein, H; Oberhoff, C; Fischer, JT; Schulze, M; Clemens, M; Andreesen, R; Mahlke, M; König, M; Scharl, A; Fehnle, K; Kaufmann, M Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial.
Ann Oncol. 2002; 13(11):1717-1729 Doi: 10.1096/annonc/mdf306 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

1999

Prior, C; Oroszy, S; Oberaigner, W; Ambrosch, G; Mohn-Staudner, A; Pfeifer, W; Pirker, R; Huber, H Advanced non-small-cell lung cancer: adjunctive interferon gamma in induction and maintenance therapy.
J Cancer Res Clin Oncol. 1999; 125(1):42-46 Doi: 10.1007%2Fs004320050240
Web of Science PubMed FullText FullText_MUG

 

1995

Zoubek, A; Kajtar, P; Flucher-Wolfram, B; Holzinger, B; Mostbeck, G; Thun-Hohenstein, L; Fink, FM; Urban, C; Mutz, I; Schuler, D Response of untreated stage IV Wilms' tumor to single dose carboplatin assessed by up front window therapy.
Med Pediatr Oncol. 1995; 25(1):8-11 Doi: 10.1002/mpo.2950250103
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1987

Hörmann, M; Hackl, A; Ranner, G; Pongratz, M Combination radiochemotherapy in the limited-disease stage of small-cell bronchial carcinoma. Results following high-dosage radiotherapy
Strahlenther Onkol. 1987; 163(5):292-296
Web of Science PubMed

 

Show the next 50 results of search

↑ Top of page / Navigation

© Med Uni Graz • Imprint